Kenneth G. Payie

Dr. Ken Payie has nearly two decades in the Biotech and Pharma industry in a variety of research and development positions. He has worked on the CM&C activities with AgeneBio since 2013. With a background in large and small molecule Chemistry Manufacturing & Controls (CM&C) development, virtual drug development experience, and Six Sigma Black Belt training and execution, Ken has developed a number of large and small molecule CM&C programs in the Candidate Identification to Phase III space for both large pharma and small drug discovery companies.

He has designed and directed drug development programs through outsourcing to Asia, Europe, and North American vendors, and significantly reduced costs to develop assets without compromising Quality. In 2011, Ken founded KGP-Biotech Consulting LLC to bring his CM&C expertise to the scientific and drug development communities. In addition to KGP-Biotech Consulting, Ken has held positions of increasing responsibility at Mapp Biopharmaceutical, Eli Lilly, and the Eli Lilly joint venture company -Vanthys Pharmaceutical based in India.